(Q35840621)

10 August 2017

1 reference

title

Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action (English)

1 reference

10 August 2017

Michael B Sporn

1

1 reference

10 August 2017

Sherie A Dowsett

series ordinal

2

1 reference

10 August 2017

John Mershon

series ordinal

3

1 reference

10 August 2017

Henry U Bryant

series ordinal

4

1 reference

10 August 2017

1 June 2004

1 reference

10 August 2017

11

1 reference

inferred from page(s)

published in

Clinical Therapeutics

1 reference

10 August 2017

26

1 reference

10 August 2017

830-840

1 reference

10 August 2017

6

1 reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Hormone replacement therapy regimens and breast cancer risk(1).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Crosstalk between the insulin-like growth factors and estrogens in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Estrogen receptor beta--a new dimension in estrogen mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Production and actions of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Biomedicine. Defining the "S" in SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Molecular determinants for the tissue specificity of SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Estrogen receptor pathways to AP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Mechanisms of tamoxifen-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Overexpression of phospholipase D1 in human breast cancer tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Influence of the antioestrogen tamoxifen on normal breast tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990127-0

7 January 2021

10.1016/S0149-2918(04)90127-0

Identifiers

DOI

1 reference

10 August 2017

1 reference